Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major health problem associated with obesity and other features of the metabolic syndrome including insulin resistance and dyslipidemia. The accumulation of lipids in hepatocytes causes liver damage and triggers inflammation, fibrosis, and cirrhosis. Beside fatty acids and triglycerides, evidence showed an increased accumulation of free cholesterol in the liver with subsequent toxic effects contributing to liver damage. The maintenance of cholesterol homeostasis in the body requires a balance between several pathways responsible for cholesterol synthesis, transport and conversion into bile acids. Intestinal absorption is also one of the major determinants of cholesterol homeostasis. The nature of changes in cholesterol homeostasis associated with NAFLD has been a subject of extensive investigations. In this article, we will attempt to provide a brief overview of the current knowledge about the disturbances in cholesterol metabolism associated with NAFLD and discuss how certain molecular targets of these pathways could be exploited for the treatment of this multifactorial disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms and regulation of cholesterol homeostasis
Luo, J., Yang, H., & Song, B.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0190-7 · Cited by 1,980
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471 · cited 1×
“It is widely accepted that increased flux of fatty acids associated with insulin resistance and/or increased de novo lipogenesis in the liver lead to fatty acid accumulation in the liver with associated lipotoxicity (5).”
BackgroundA lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 1×
“(24) showed high levels of free cholesterol in patients with NAFLD (simple steatosis) that were more pronounced in cases with progressive form of the disease, NASH.”
BackgroundSimvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241 · cited 10×
“Studies showed that the inhibitor of cholesterol absorption ezetimibe reduces plasma cholesterol and decreases the risk of CVD when used alone or in combination with statins (67, 68).”
BackgroundInfluentialPlasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
The Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498
Statin use and non-alcoholic steatohepatitis in at risk individuals
Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R. M., Pipitone, R., Karja, V., Maggioni, M., Kakela, P., Wiklund, O., Mozzi, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.006 · Cited by 390 · cited 2×
“However, recent studies in a cohort of ∼1,200 European patients provided strong evidence demonstrating the beneficial effects of statins in the protection against steatosis, steatohepatitis, and fibrosis as assessed by liver biopsies (50).”
BackgroundBohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Fan, J., Kitajima, S., Watanabe, T., Xu, J., Zhang, J., Liu, E., & Chen, Y. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.009 · Cited by 333 · cited 2×
“More importantly, rabbits are sensitive to dietary cholesterol and develop severe hypercholesterolemia in response to high dietary cholesterol with prominent atherosclerosis (16).”
BackgroundIntestinal absorption of bile acids in health and disease
Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215 · cited 3×
“Inhibitors of Bile Acid Absorption Blocking the absorption of bile acids eliminates the negative feedback inhibition on their hepatic synthesis and promotes cholesterol degradation (12).”
BackgroundSelf-citation
Cited by
Costello, E., Rock, S., Stratakis, N., Eckel, S. P., Walker, D. I., Valvi, D., Cserbik, D., Jenkins, T., Xanthakos, S. A., Kohli, R., et al. (2022) · Environmental Health Perspectives · doi:10.1289/ehp10092 · Cited by 420
“34 48 – 50 Indeed, the association between PFAS exposure and NAFLD in humans remains challenging to evaluate given the di ffi culty in obtaining biopsy-con fi rmed NAFLD histological data, and thus liver injury is typically assessed using serum biomarkers of hepatotoxicity or imaging assessments of…”
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Okoro, E. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126236 · Cited by 18
Metadata
- Authors
- Malhotra, P., Gill, R. K., Saksena, S., & Alrefai, W. A.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2020-09-02
- Volume
- 7
- Pages
- 467-467
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W3081831430
- Cited by
- 109
- References
- 12
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.